The future of real-world research is now
ESMO is at the forefront of digital oncology, with some initiatives that support oncologists navigating the emerging opportunities in the field of real-world data research
Being good as a role model does not depend on gender
ESMO Women for Oncology Awardee Prof. Georgina Long talks of addressing gender bias in oncology
The emerging role of ctDNA in breast cancer
Liquid biopsies hold great promise in precision medicine in breast cancer, as shown by the pioneering work of Prof. Nicholas Turner, recipient of the ESMO Award for Translational Research 2023
Three decades of progress in nasopharyngeal cancer
Tailored management for high-risk locoregional disease, together with more effective immunotherapy combinations are key areas of exploration in nasopharyngeal cancer, according to 2023 ESMO Lifetime Achievement awardee Prof. Anthony Chan
Research promotion and good partnerships have brought rare gynaecological malignancies into the light
According to Prof. Isabelle Ray-Coquard, 2023 ESMO Awardee, the many efforts made in recent years are finally increasing treatment options for patients
Clonal haematopoiesis in the tumour microenvironment is an indicator of poor prognosis in NSCLC
Results from the TRACERx study suggest a potential role of CHIP as a prognostic biomarker, but further research is needed
Complete molecular characterisation is feasible for many cancer patients, study suggests
In the MATCH-R study, comprehensive profiling included successful sequencing of DNA and also of RNA, enabling the detection of actionable genomic alterations
Single-cell DNA sequencing confirms considerable intratumoural heterogeneity in breast cancer
The study involved patients with HR-positive/HER2-negative localised disease, but additional analyses are required to describe implications for clinical practice.
Precision oncology – are we at an inflection point?
At Molecular Analysis for Precision Oncology (MAP) Congress 2023, international experts discuss the future of histology-agnostic drug development and clinical trial design
Exploiting knowledge of neutrophil protumour and antitumour phenotypes to treat cancer
Identifying the trigger that switches neutrophils from protumour to antitumour activity in the tumour microenvironment could open the door to new therapeutic options